CyberKnife radiosurgery as a first treatment for idiopathic trigeminal neuralgia

Laura Fariselli, Carlo Marras, Michela De Santis, Marcello Marchetti, Ida Milanesi, Giovanni Broggi

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To report the level of effectiveness and safety, in our experience, of CyberKnife (Accuray, Inc., Sunnyvale, CA) robotic radiosurgery as a first-line treatment against pharmacologically refractory trigeminal neuralgia. METHODS: We treated 33 patients with the frameless CyberKnife system as a monotherapy. The retrogasserian portion of the trigeminal nerve (a length of 4 mm, 2-3 mm anterior to the root entry zone) was targeted. Doses of 55 to 75 Gy were prescribed to the 100% isodose line, according to a dose escalation protocol. The patients were evaluated for the level of pain control, time to pain relief, hypesthesia, and time to pain recurrence. RESULTS: The median age was 74 years. All but 2 patients (94%) achieved a successful treatment outcome. The follow-up period was 9 to 37 months (mean, 23 months). The Barrow Neurological Institute Rain Intensity Scale (BPS) score before radiosurgery was III in 2 patients (6%), IV in 8 patients (24%), and V in 23 patients (70%). The time to pain relief was 1 to 180 days (median, 30 days). No facial numbness was observed. Only 1 patient developed a transitory dysesthesia of the tongue. After treatment, the BPS score was I, II, or III in 31 patients (97%). Pain recurred in 33% (11 patients) at a mean of 9 months (range, 1-43 months). Three patients with recurrences had low pain control by medication (BPS score, IV), and 1 patient (BPS score, V) needed a radiofre-quency lesioning (BPS score, I at 12 months). CONCLUSION: CyberKnife radiosurgery for trigeminal neuralgia allows pain relief at safe doses and is suggested for pharmacologically refractory trigeminal neuralgia. Higher prescribed doses were not associated with improvement in pain relief or recurrence rate.

Original languageEnglish
JournalNeurosurgery
Volume64
Issue number2 SUPPL.
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Trigeminal Neuralgia
Radiosurgery
Pain
Therapeutics
Hypesthesia
Recurrence
Trigeminal Nerve
Rain
Paresthesia
Robotics
Tongue

Keywords

  • Cyberknife
  • Racial pain
  • Radiosurgical rhizotomy
  • Stereotactic radiosurgery
  • Trigeminal neuralgia

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

CyberKnife radiosurgery as a first treatment for idiopathic trigeminal neuralgia. / Fariselli, Laura; Marras, Carlo; De Santis, Michela; Marchetti, Marcello; Milanesi, Ida; Broggi, Giovanni.

In: Neurosurgery, Vol. 64, No. 2 SUPPL., 02.2009.

Research output: Contribution to journalArticle

@article{6a6ec1e900d646459a1c9f7d3c385216,
title = "CyberKnife radiosurgery as a first treatment for idiopathic trigeminal neuralgia",
abstract = "OBJECTIVE: To report the level of effectiveness and safety, in our experience, of CyberKnife (Accuray, Inc., Sunnyvale, CA) robotic radiosurgery as a first-line treatment against pharmacologically refractory trigeminal neuralgia. METHODS: We treated 33 patients with the frameless CyberKnife system as a monotherapy. The retrogasserian portion of the trigeminal nerve (a length of 4 mm, 2-3 mm anterior to the root entry zone) was targeted. Doses of 55 to 75 Gy were prescribed to the 100{\%} isodose line, according to a dose escalation protocol. The patients were evaluated for the level of pain control, time to pain relief, hypesthesia, and time to pain recurrence. RESULTS: The median age was 74 years. All but 2 patients (94{\%}) achieved a successful treatment outcome. The follow-up period was 9 to 37 months (mean, 23 months). The Barrow Neurological Institute Rain Intensity Scale (BPS) score before radiosurgery was III in 2 patients (6{\%}), IV in 8 patients (24{\%}), and V in 23 patients (70{\%}). The time to pain relief was 1 to 180 days (median, 30 days). No facial numbness was observed. Only 1 patient developed a transitory dysesthesia of the tongue. After treatment, the BPS score was I, II, or III in 31 patients (97{\%}). Pain recurred in 33{\%} (11 patients) at a mean of 9 months (range, 1-43 months). Three patients with recurrences had low pain control by medication (BPS score, IV), and 1 patient (BPS score, V) needed a radiofre-quency lesioning (BPS score, I at 12 months). CONCLUSION: CyberKnife radiosurgery for trigeminal neuralgia allows pain relief at safe doses and is suggested for pharmacologically refractory trigeminal neuralgia. Higher prescribed doses were not associated with improvement in pain relief or recurrence rate.",
keywords = "Cyberknife, Racial pain, Radiosurgical rhizotomy, Stereotactic radiosurgery, Trigeminal neuralgia",
author = "Laura Fariselli and Carlo Marras and {De Santis}, Michela and Marcello Marchetti and Ida Milanesi and Giovanni Broggi",
year = "2009",
month = "2",
doi = "10.1227/01.NEU.0000341714.55023.8F",
language = "English",
volume = "64",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "2 SUPPL.",

}

TY - JOUR

T1 - CyberKnife radiosurgery as a first treatment for idiopathic trigeminal neuralgia

AU - Fariselli, Laura

AU - Marras, Carlo

AU - De Santis, Michela

AU - Marchetti, Marcello

AU - Milanesi, Ida

AU - Broggi, Giovanni

PY - 2009/2

Y1 - 2009/2

N2 - OBJECTIVE: To report the level of effectiveness and safety, in our experience, of CyberKnife (Accuray, Inc., Sunnyvale, CA) robotic radiosurgery as a first-line treatment against pharmacologically refractory trigeminal neuralgia. METHODS: We treated 33 patients with the frameless CyberKnife system as a monotherapy. The retrogasserian portion of the trigeminal nerve (a length of 4 mm, 2-3 mm anterior to the root entry zone) was targeted. Doses of 55 to 75 Gy were prescribed to the 100% isodose line, according to a dose escalation protocol. The patients were evaluated for the level of pain control, time to pain relief, hypesthesia, and time to pain recurrence. RESULTS: The median age was 74 years. All but 2 patients (94%) achieved a successful treatment outcome. The follow-up period was 9 to 37 months (mean, 23 months). The Barrow Neurological Institute Rain Intensity Scale (BPS) score before radiosurgery was III in 2 patients (6%), IV in 8 patients (24%), and V in 23 patients (70%). The time to pain relief was 1 to 180 days (median, 30 days). No facial numbness was observed. Only 1 patient developed a transitory dysesthesia of the tongue. After treatment, the BPS score was I, II, or III in 31 patients (97%). Pain recurred in 33% (11 patients) at a mean of 9 months (range, 1-43 months). Three patients with recurrences had low pain control by medication (BPS score, IV), and 1 patient (BPS score, V) needed a radiofre-quency lesioning (BPS score, I at 12 months). CONCLUSION: CyberKnife radiosurgery for trigeminal neuralgia allows pain relief at safe doses and is suggested for pharmacologically refractory trigeminal neuralgia. Higher prescribed doses were not associated with improvement in pain relief or recurrence rate.

AB - OBJECTIVE: To report the level of effectiveness and safety, in our experience, of CyberKnife (Accuray, Inc., Sunnyvale, CA) robotic radiosurgery as a first-line treatment against pharmacologically refractory trigeminal neuralgia. METHODS: We treated 33 patients with the frameless CyberKnife system as a monotherapy. The retrogasserian portion of the trigeminal nerve (a length of 4 mm, 2-3 mm anterior to the root entry zone) was targeted. Doses of 55 to 75 Gy were prescribed to the 100% isodose line, according to a dose escalation protocol. The patients were evaluated for the level of pain control, time to pain relief, hypesthesia, and time to pain recurrence. RESULTS: The median age was 74 years. All but 2 patients (94%) achieved a successful treatment outcome. The follow-up period was 9 to 37 months (mean, 23 months). The Barrow Neurological Institute Rain Intensity Scale (BPS) score before radiosurgery was III in 2 patients (6%), IV in 8 patients (24%), and V in 23 patients (70%). The time to pain relief was 1 to 180 days (median, 30 days). No facial numbness was observed. Only 1 patient developed a transitory dysesthesia of the tongue. After treatment, the BPS score was I, II, or III in 31 patients (97%). Pain recurred in 33% (11 patients) at a mean of 9 months (range, 1-43 months). Three patients with recurrences had low pain control by medication (BPS score, IV), and 1 patient (BPS score, V) needed a radiofre-quency lesioning (BPS score, I at 12 months). CONCLUSION: CyberKnife radiosurgery for trigeminal neuralgia allows pain relief at safe doses and is suggested for pharmacologically refractory trigeminal neuralgia. Higher prescribed doses were not associated with improvement in pain relief or recurrence rate.

KW - Cyberknife

KW - Racial pain

KW - Radiosurgical rhizotomy

KW - Stereotactic radiosurgery

KW - Trigeminal neuralgia

UR - http://www.scopus.com/inward/record.url?scp=61449266529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449266529&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000341714.55023.8F

DO - 10.1227/01.NEU.0000341714.55023.8F

M3 - Article

C2 - 19165081

AN - SCOPUS:61449266529

VL - 64

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 2 SUPPL.

ER -